EA202090782A1 - METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO THERAPY DIRECTED TO THE ANDROGEN RECEPTOR - Google Patents

METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO THERAPY DIRECTED TO THE ANDROGEN RECEPTOR

Info

Publication number
EA202090782A1
EA202090782A1 EA202090782A EA202090782A EA202090782A1 EA 202090782 A1 EA202090782 A1 EA 202090782A1 EA 202090782 A EA202090782 A EA 202090782A EA 202090782 A EA202090782 A EA 202090782A EA 202090782 A1 EA202090782 A1 EA 202090782A1
Authority
EA
Eurasian Patent Office
Prior art keywords
androgen receptor
methods
modified
compositions
receptor polypeptides
Prior art date
Application number
EA202090782A
Other languages
Russian (ru)
Inventor
Джеймс Дэвид Джозеф
Джеффри Х. Хэджер
Джон Ли Сенсинтаффар
Нхин Лу
Цзин Циань
Николас Д. Смит
Original Assignee
Арагон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арагон Фармасьютикалз, Инк. filed Critical Арагон Фармасьютикалз, Инк.
Publication of EA202090782A1 publication Critical patent/EA202090782A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении описаны модифицированные полипептиды андрогенного рецептора, которые являются резистентными к ингибированию ингибитором андрогенного рецептора. В настоящем документе описаны композиции, комбинации и наборы, содержащие модифицированные полипептиды андрогенного рецептора, а также способы применения модифицированных полипептидов андрогенного рецептора. В настоящем документе также описаны способы применения модифицированных полипептидов андрогенного рецептора в качестве агентов скрининга для выявления и конструирования модуляторов андрогенного рецептора третьего поколения. В настоящем документе также описаны модуляторы андрогенного рецептора третьего поколения, которые ингибируют активность модифицированных полипептидов андрогенного рецептора. Также описаны фармацевтические композиции и лекарственные средства, которые включают описанные в настоящем документе соединения, а также способы применения таких модуляторов андрогенного рецептора самостоятельно или в комбинации с другими соединениями для лечения заболеваний или состояний, включая онкологические заболевания, такие как кастрационно-резистентный рак предстательной железы, которые опосредованы или зависят от андрогенных рецепторов.The present invention describes modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. This document describes compositions, combinations and kits containing modified androgen receptor polypeptides, as well as methods of using the modified androgen receptor polypeptides. Methods of using modified androgen receptor polypeptides as screening agents for the detection and design of third generation androgen receptor modulators are also described herein. This document also describes third generation androgen receptor modulators that inhibit the activity of modified androgen receptor polypeptides. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone or in combination with other compounds, to treat diseases or conditions, including cancers such as castration-resistant prostate cancer, which are mediated or dependent on androgen receptors.

EA202090782A 2013-05-30 2013-07-26 METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO THERAPY DIRECTED TO THE ANDROGEN RECEPTOR EA202090782A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361829123P 2013-05-30 2013-05-30

Publications (1)

Publication Number Publication Date
EA202090782A1 true EA202090782A1 (en) 2020-07-31

Family

ID=71833548

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090782A EA202090782A1 (en) 2013-05-30 2013-07-26 METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO THERAPY DIRECTED TO THE ANDROGEN RECEPTOR

Country Status (1)

Country Link
EA (1) EA202090782A1 (en)

Similar Documents

Publication Publication Date Title
EA201792520A2 (en) METHODS AND COMPOSITIONS FOR DETERMINATION OF RESISTANCE TO THERAPY, AIMED AT AN ANDROGENIC RECEPTOR
EA201491530A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
EA201270815A1 (en) ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
EA201891397A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS OF ANTAGONISTS ANDROGEN RECEPTORS
HN2011000074A (en) FGF-R4 RECEIVER SPECIFIC ANTAGONISTS
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
EA201491161A1 (en) FLUORINATED ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
EA201500835A1 (en) THERAPEUTIC AND DIAGNOSTIC TARGET TARGET, INCLUDING DLL3-BINDING REAGENTS
BR112012020558A2 (en) androgen receptor modulators and their uses
CR20170216A (en) ANTI-TARGET COMPOSITIONS
MX2015014046A (en) Drug combinations to treat cancer.
PH12019502692A1 (en) Anti-cancer combination therapy
CR20170218A (en) ANTI-TARGET COMPOSITIONS
MX2015012274A (en) Androgen receptor down-regulating agents and uses thereof.
EA201791227A1 (en) DOSING MODE OF MAdCAM ANTAGONISTS
EA201792380A1 (en) NEW EPHA4 INHIBITORS AIMED AT HIS LIGAND-BINDING DOMAIN
EA202090782A1 (en) METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE TO THERAPY DIRECTED TO THE ANDROGEN RECEPTOR
EA201992835A1 (en) ANTI-CANCER COMBINED THERAPY
EA202092853A1 (en) DOSING MODE OF THE MAdCAM ANTAGONISTS
UA118368C2 (en) METHOD OF DETERMINING AR-THERAPY RESISTANCE